Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cardiovascular diseases

A simple tool to screen for heart failure with preserved ejection fraction

Nature Medicine volume 30, pages 2127–2128 (2024)Cite this article

Subjects

For patients with shortness of breath, a new, simplified screening tool — relying only on basic clinical information — can estimate the probability of heart failure with preserved ejection fraction, providing the opportunity for improved detection in non-specialist settings.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Implementation of the HFpEF-ABA score to screen for patients with heart failure with preserved ejection fraction.

References

  1. Bozkurt, B. et al. J. Card. Fail. 29, 1412–1451 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kittleson, M. M. et al. J. Am. Coll. Cardiol. 81, 1835–1878 (2023).

    Article  PubMed  Google Scholar 

  3. Heidenreich, P. A. et al. J. Am. Coll. Cardiol. 79, e263–e421 (2022).

    Article  PubMed  Google Scholar 

  4. Pieske, B. et al. Eur. Heart J. 40, 3297–3317 (2019).

    Article  PubMed  Google Scholar 

  5. Reddy, Y. N. V., Carter, R. E., Obokata, M., Redfield, M. M. & Borlaug, B. A. Circulation 138, 861–870 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Reddy, Y. N. V. et al. Nat. Med. https://doi.org/10.1038/s41591-024-03140-1 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Ramalho, S. H. R. et al. JAMA Netw. Open 2, e195321 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Kosiborod, M. N. et al. N. Engl. J. Med. 389, 1069–1084 (2023).

    Article  CAS  PubMed  Google Scholar 

  9. Solomon, S. D. et al. N. Engl. J. Med. 387, 1089–1098 (2022).

    Article  PubMed  Google Scholar 

  10. Pandey, A. et al. Circulation 141, 1295–1306 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Khan, M. S. et al. JACC Heart Fail. 11, 825–835 (2023).

    Article  PubMed  Google Scholar 

  12. McGuire, D. K. et al. JAMA Cardiol. 6, 148–158 (2021).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Ambarish Pandey

  2. Section of Cardiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

    Shelley Zieroth

Authors
  1. Ambarish Pandey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shelley Zieroth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ambarish Pandey.

Ethics declarations

Competing interests

A.P. has received research support from the National Institute of Health. A.P has received grant funding from Applied Therapeutics and Gilead Sciences; has received honoraria outside of the present study as an advisor/consultant for Tricog Health Inc, Lilly USA, Rivus, Cytokinetics, Roche Diagnostics, Axon therapies, Medtronic, Edward Lifesciences, Science37, Novo Nordisk, Bayer, Merck, Sarfez Pharmaceuticals and Emmi Solutions; and has received nonfinancial support from Pfizer and Merck. A.P. is also a consultant for Palomarin Inc. with stocks compensation. S.Z. has received research grant support; served on advisory boards for or had speaker engagements with Abbott, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Cytokinetics, Eli Lilly, GSK, Medtronic, Merck, Novartis, Novo-Nordisk, Pfizer and Vifor Pharma; and serves on a clinical trial committee or as a national lead for studies sponsored by AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Pfizer and Salubris Bio.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pandey, A., Zieroth, S. A simple tool to screen for heart failure with preserved ejection fraction. Nat Med 30, 2127–2128 (2024). https://doi.org/10.1038/s41591-024-03154-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-024-03154-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing